MedTrace Logo

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LINO-1713 in Healthy Korean Female Subjects

NCT05677035 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-01-11

No results posted yet for this study

Summary

A single-center, open-label, parallel-group, phase 1 study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of LINO-1713 in healthy Korean female subjects

Conditions

  • Contraception

Interventions

DRUG

LINO-1713 1 tablet

LINO-1713 1 tablet is administered once. Oral administration with 200mL of water

DRUG

LINO-1713 once a day for 24 days

Oral administration is performed with 200 mL of water. Instruct subjects to take the drug at the same time as possible.

Sponsors & Collaborators

  • Hyundai Pharm

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-11
Primary Completion
2022-06-15
Completion
2022-06-15

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05677035 on ClinicalTrials.gov